Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Segment 2 from influenza A(H1N1) 2009 pandemic viruses confers temperature-sensitive haemagglutinin yield on candidate vaccine virus growth in eggs that can be epistatically complemented by PB2 701D.

Hussain S, Turnbull ML, Pinto RM, McCauley JW, Engelhardt OG, Digard P.

J Gen Virol. 2019 Jul;100(7):1079-1092. doi: 10.1099/jgv.0.001279. Epub 2019 Jun 6.

PMID:
31169484
2.

Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.

Bhide Y, Dong W, Gribonika I, Voshart D, Meijerhof T, de Vries-Idema J, Norley S, Guilfoyle K, Skeldon S, Engelhardt OG, Boon L, Christensen D, Lycke N, Huckriede A.

Front Immunol. 2019 Mar 29;10:646. doi: 10.3389/fimmu.2019.00646. eCollection 2019.

3.

Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study.

McDonald JU, Rigsby P, Dougall T, Engelhardt OG; Study Participants.

Vaccine. 2018 Nov 29;36(50):7641-7649. doi: 10.1016/j.vaccine.2018.10.087. Epub 2018 Oct 30.

4.

Mutation of Influenza A Virus PA-X Decreases Pathogenicity in Chicken Embryos and Can Increase the Yield of Reassortant Candidate Vaccine Viruses.

Hussain S, Turnbull ML, Wise HM, Jagger BW, Beard PM, Kovacikova K, Taubenberger JK, Vervelde L, Engelhardt OG, Digard P.

J Virol. 2019 Jan 4;93(2). pii: e01551-18. doi: 10.1128/JVI.01551-18. Print 2019 Jan 15.

5.

Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.

Dong W, Bhide Y, Sicca F, Meijerhof T, Guilfoyle K, Engelhardt OG, Boon L, de Haan CAM, Carnell G, Temperton N, de Vries-Idema J, Kelvin D, Huckriede A.

Front Immunol. 2018 Oct 9;9:2312. doi: 10.3389/fimmu.2018.02312. eCollection 2018.

6.

Workshop report: Experimental animal models for universal influenza vaccines.

D'Alessio F, Koopman G, Houard S, Remarque EJ, Stockhofe N, Engelhardt OG.

Vaccine. 2018 Nov 12;36(46):6895-6901. doi: 10.1016/j.vaccine.2018.10.024. Epub 2018 Oct 16.

PMID:
30340885
7.

Comparison of single radial immunodiffusion, SDS-PAGE and HPLC potency assays for inactivated influenza vaccines shows differences in ability to predict immunogenicity of haemagglutinin antigen.

Engelhardt OG, Edge C, Dunleavy U, Guilfoyle K, Harvey R, Major D, Newman R, Penn R, Skeldon S, Storey C, Wheeler J, Wood J, Minor P.

Vaccine. 2018 Jul 5;36(29):4339-4345. doi: 10.1016/j.vaccine.2018.05.076. Epub 2018 Jun 9.

8.

Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016.

Ortiz JR, Hickling J, Jones R, Donabedian A, Engelhardt OG, Katz JM, Madhi SA, Neuzil KM, Rimmelzwaan GF, Southern J, Spiro DJ, Hombach J.

Vaccine. 2018 Feb 8;36(7):932-938. doi: 10.1016/j.vaccine.2017.11.061. Epub 2017 Dec 6.

9.

Workshop report: Immunoassay standardisation for "universal" influenza vaccines.

Pavlova S, D'Alessio F, Houard S, Remarque EJ, Stockhofe N, Engelhardt OG.

Influenza Other Respir Viruses. 2017 May;11(3):194-201. doi: 10.1111/irv.12445. Epub 2017 Apr 8. Review.

10.

The Ability of a Non-Egg Adapted (Cell-Like) A(H1N1)pdm09 Virus to Egg-Adapt at HA Loci Other than 222 and 223 and Its Effect on the Yield of Viral Protein.

Nicolson C, Harvey R, Engelhardt OG, Robertson JS.

PLoS One. 2016 Nov 18;11(11):e0166761. doi: 10.1371/journal.pone.0166761. eCollection 2016.

11.

CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement.

Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee.

Influenza Other Respir Viruses. 2017 Jan;11(1):2-14. doi: 10.1111/irv.12411. Epub 2016 Aug 9.

12.

Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity.

Eichelberger MC, Couzens L, Gao Y, Levine M, Katz J, Wagner R, Thompson CI, Höschler K, Laurie K, Bai T, Engelhardt OG; ELLA study participants, Wood J.

Vaccine. 2016 Jan 20;34(4):458-465. doi: 10.1016/j.vaccine.2015.12.022. Epub 2015 Dec 18.

13.

Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.

Ampofo WK, Azziz-Baumgartner E, Bashir U, Cox NJ, Fasce R, Giovanni M, Grohmann G, Huang S, Katz J, Mironenko A, Mokhtari-Azad T, Sasono PM, Rahman M, Sawanpanyalert P, Siqueira M, Waddell AL, Waiboci L, Wood J, Zhang W, Ziegler T; WHO Writing Group.

Vaccine. 2015 Aug 26;33(36):4368-82. doi: 10.1016/j.vaccine.2015.06.090. Epub 2015 Jul 3.

14.

International Laboratory Comparison of Influenza Microneutralization Assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) Influenza Viruses by CONSISE.

Laurie KL, Engelhardt OG, Wood J, Heath A, Katz JM, Peiris M, Hoschler K, Hungnes O, Zhang W, Van Kerkhove MD; CONSISE Laboratory Working Group participants.

Clin Vaccine Immunol. 2015 Aug;22(8):957-64. doi: 10.1128/CVI.00278-15. Epub 2015 Jun 24.

15.

A promoter mutation in the haemagglutinin segment of influenza A virus generates an effective candidate live attenuated vaccine.

Harvey R, Johnson RE, MacLellan-Gibson K, Robertson JS, Engelhardt OG.

Influenza Other Respir Viruses. 2014 Nov;8(6):605-12. doi: 10.1111/irv.12274. Epub 2014 Aug 2.

16.

The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency.

Hufton SE, Risley P, Ball CR, Major D, Engelhardt OG, Poole S.

PLoS One. 2014 Aug 1;9(8):e103294. doi: 10.1371/journal.pone.0103294. eCollection 2014.

17.

WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013.

Barr IG, Russell C, Besselaar TG, Cox NJ, Daniels RS, Donis R, Engelhardt OG, Grohmann G, Itamura S, Kelso A, McCauley J, Odagiri T, Schultz-Cherry S, Shu Y, Smith D, Tashiro M, Wang D, Webby R, Xu X, Ye Z, Zhang W; Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2013–2014.

Vaccine. 2014 Aug 20;32(37):4713-25. doi: 10.1016/j.vaccine.2014.02.014. Epub 2014 Feb 28.

18.

The consortium for the standardization of influenza seroepidemiology (CONSISE): a global partnership to standardize influenza seroepidemiology and develop influenza investigation protocols to inform public health policy.

Van Kerkhove MD, Broberg E, Engelhardt OG, Wood J, Nicoll A; CONSISE steering committee.

Influenza Other Respir Viruses. 2013 May;7(3):231-4. doi: 10.1111/irv.12068. Epub 2012 Dec 26.

19.

WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011.

Klimov AI, Garten R, Russell C, Barr IG, Besselaar TG, Daniels R, Engelhardt OG, Grohmann G, Itamura S, Kelso A, McCauley J, Odagiri T, Smith D, Tashiro M, Xu X, Webby R, Wang D, Ye Z, Yuelong S, Zhang W, Cox N; Writing Committee of the World Health Organization Consultation on Southern Hemisphere Influenza Vaccine Composition for 2012.

Vaccine. 2012 Oct 5;30(45):6461-71. doi: 10.1016/j.vaccine.2012.07.089. Epub 2012 Aug 20.

20.

Many ways to make an influenza virus--review of influenza virus reverse genetics methods.

Engelhardt OG.

Influenza Other Respir Viruses. 2013 May;7(3):249-56. doi: 10.1111/j.1750-2659.2012.00392.x. Epub 2012 Jun 19. Review.

Supplemental Content

Loading ...
Support Center